Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Mol Cancer Ther. 2012 Aug 6;11(11):2516–2525. doi: 10.1158/1535-7163.MCT-12-0494

Figure 1. CXCL122 inhibits CXCR4-B16 metastasis more effectively than wtCXCL12 and AMD3100.

Figure 1

(A) CXCR4-luc-B16-F10 cells (4 × 105) were injected i.v. into the tail vein of C57BL/6 mouse with the indicated concentrations of drugs. On day 1, the animals were given the same treatment i.v. Lungs were harvested 14 days after inoculation, and luciferase activity was measured to evaluate metastatic tumor. (B) CXCL122 (n=4), (C) wtCXCL12 (n=4), and (D) AMD3100 data (vehicle: n=9, others: n=8, Data is a summation of 2 independent experiments) are shown. (E) Representative lung images from mice treated with each drug are shown. (F) Calcium response of CXCR4-luc-B16-F1 cells induced by 500 nM CXCL122 or wtCXCL12 was measured in the presence and absence of 5 μM AMD3100. Experiments were recorded in quadruplicate on two separate days. Tumor burden was assessed by measuring luciferase-dependent light production using relative light units (RLU).